Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
33.50    -0.50 (-1.47%)
Bid:
32.00
Ask:
35.00
Spread: 3.00 (9.375%)
Market Cap: £15.60m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

Replacement - Director/PDMR Shareholding

29 Sep 2014 12:40

RNS Number : 8666S
Cambridge Cognition Holdings PLC
29 September 2014
 



 

 

The following amendment has been made to the 'Directors/PDMR Shareholding' announcement released on 29 September 2014 at 10.06 under RNS No 8443S. Nick Kerton's total beneficial interest has been corrected to 127,285 Ordinary Shares representing 0.75% of issued share capital of the Company.

 

 

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

 

Directors/PDMR Shareholding

 

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests, was notified on 26 September 2014 of the following transactions by Directors.

 

Nick Kerton, Chief Executive Officer, purchased 55,000 ordinary shares at a price of 65.5 pence each. Following this notification, Mr Kerton now has a total beneficial interest of 127,285 Ordinary Shares representing 0.75% of the issued share capital of the Company.

 

Nick Walters, Chief Financial Officer, purchased 45,000 ordinary shares at a price of 65.5 pence each. Following this notification, Mr Walters has a total beneficial interest of 92,000 Ordinary Shares representing 0.54% of the issued share capital of the Company.

 

Cambridge Cognition's capital consists of 16,930,556 Ordinary Shares with voting rights. The Company does not hold any Ordinary Shares in Treasury.

 

 

 

 

Enquiries:

 

Cambridge Cognition Holdings plc

www.cambridgecognition.com

Nick Kerton, Chief Executive Officer

Tel: 01223 810 700

Nick Walters, Chief Financial Officer

finnCap Ltd (Nomad and Broker)

Tel: 020 7220 0500

Matthew Robinson/Henrik Persson/Simon Hicks

(Corporate Finance)

Elizabeth Johnson

(Corporate Broking)

Walbrook PR Ltd

Tel: 020 7933 8780 or camcog@walbrookpr.com

Paul McManus

Mob: 07584 391 303

Lianne Cawthorne

Mob: 07584 391 303

 

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEAFNNADKLEFF
Date   Source Headline
7th Mar 20197:00 amRNSPreliminary Results
31st Jan 20197:00 amRNSFirst Partnership in India and New Product Launch
19th Dec 20187:00 amRNSTrading update and notice of results
14th Nov 20187:00 amRNSContract win in growing eCOA revenue stream
20th Sep 20187:00 amRNSHalf Yearly Report
19th Sep 20187:00 amRNSCompany signs first NeuroVocalix contract
13th Sep 20187:00 amRNSNeuroVocalixT platform ready for clinical trials
1st Aug 20187:00 amRNSCANTAB incorporated in population health platform
20th Jun 20187:00 amRNSNew product to improve workplace mental health
7th Jun 20187:00 amRNSPartnership to tackle growing mental health need
31st May 20187:00 amRNSNew client signs with Cognition Kit software
24th May 201812:24 pmRNSResult of AGM
9th May 201811:34 amRNSHolding(s) in Company
3rd May 20187:00 amRNSDirector/PDMR Shareholding
2nd May 20187:00 amRNSPosting of Annual Report & Notice of AGM
12th Apr 20181:20 pmRNSHolding(s) in Company
12th Apr 201810:20 amRNSHolding(s) in Company
10th Apr 20187:00 amRNSRecruitment contracts show strong growth
26th Mar 20187:00 amRNSMajor Contract Win and Funding Award
22nd Mar 201811:05 amRNSSecond Price Monitoring Extn
22nd Mar 201811:00 amRNSPrice Monitoring Extension
22nd Mar 20187:00 amRNSFinal Results
1st Mar 20187:30 amRNSHolding(s) in Company
27th Feb 20184:25 pmRNSHolding(s) in Company
10th Jan 20187:00 amRNSTrading Update and Notice of Results
5th Dec 20178:55 amRNSHolding(s) in Company
28th Nov 20177:00 amRNSWearable technology demonstrates high compliance
2nd Nov 20177:00 amRNSGrant of Options
10th Oct 201711:00 amRNSHolding(s) in Company
10th Oct 201710:58 amRNSHolding(s) in Company
6th Oct 20177:00 amRNSIssue of Equity
21st Sep 20177:00 amRNSHalf-year Report
12th Sep 20177:00 amRNSAward of Funding
31st Aug 20177:00 amRNSNotice of Results
12th Jun 20179:56 amRNSHolding(s) in Company
8th Jun 20177:00 amRNSDirector/PDMR Shareholding
7th Jun 20177:00 amRNSSpeech recognition for clinical trials
25th May 20172:22 pmRNSResult of AGM & Board Change
24th May 20174:27 pmRNSHolding(s) in Company
22nd May 20177:00 amRNSIssue of Equity
11th May 20171:07 pmRNSHolding(s) in Company
10th May 20177:00 amRNSGrant of Options
2nd May 20177:00 amRNSPosting of Annual Report & Notice of AGM
30th Mar 20177:00 amRNSDirector/PDMR Shareholding
29th Mar 20177:00 amRNSAnnual Financial Report
16th Mar 20177:00 amRNSCANTAB used in EBBINGHAUS cognitive function trial
7th Mar 20177:00 amRNSLaunch of web-based testing for virtual research
24th Feb 20177:00 amRNSPartnership With Takeda For Wearables
23rd Feb 20177:00 amRNSNotice of Results
20th Feb 20177:00 amRNSAppointment of Joint Broker

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.